AstraZeneca CEO: Explosive Q1 China Growth Will Ease In 2H, Then Reignite
AstraZeneca generated 28% sales growth in China during the first quarter - but the UK group's CEO said that stellar performance will decline somewhat in the second half.
You may also be interested in...
Tagrisso, Lynparza and Imfinzi are enjoying stellar sales growth which is unlikely to slow down any time soon.
Q1 Earnings Preview: When AstraZeneca reports first-quarter results on April 26 investor focus will be on new product sales growth, pipeline catalysts and clues on possible fresh divestment and licensing deals.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.